Inclusion Criteria:

- Measurable unresectable Stage III or Stage IV melanoma

- ECOG Performance Status 0 or 1

- 4 weeks or greater since treatment

- Must have recovered from any acute toxicity associated with prior therapy

- Life expectancy of greater than 12 weeks

- 18 years of age or older

- Laboratory values as outlined in protocol

- Negative screening tests for HIV, active Hepatitis B and Hepatitis C

- Patients who received prior therapy with anthracyclines should have a baseline MUGA
or echo with a normal ejection fraction

Exclusion Criteria:

- CNS metastases

- Pregnant or nursing women

- Prior therapy with bevacizumab or ipilimumab

- Active infection

- Autoimmune disease: Patients with a history of inflammatory bowel disease are
excluded from this study as are patients with a history of symptomatic autoimmune
disease

- Any other malignancy from which the patient has been disease-free for less than 5
years, with the exception of adequately treated and cured basal or squamous cell skin
cancer, superficial bladder cancer or carcinoma in situ of the cervix

- Any underlying medical condition which, in the principal investigator's opinion, will
make the administration of study drug hazardous or obscure the interpretation of
adverse events

- Any concurrent medical condition requiring the use of systemic steroids

- Inadequately controlled hypertension

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

- History of stroke of transient ischemic attack within 6 months prior to study
enrollment

- Significant known vascular disease

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure or significant traumatic injury within 28 days prior to
study enrollment

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer or bone fracture

- Proteinuria at screening

- Known hypersensitivity to any component of bevacizumab

- History of hemoptysis within 3 months prior to study enrollment

- Current, ongoing treatment with full-dose warfarin or its equivalent

- Current or recent (within 10 days of enrollment) use of aspirin (>325mg/day) or
chronic use of other NSAIDs

- Medications that inhibit platelet function

- Known involvement of melanoma within gastrointestinal tract

- Ulcerated skin lesions